Impact of complete blood count sampling time change on white blood cell and absolute neutrophil count values in clozapine recipients

Clinical Schizophrenia and Related Psychoses

Volumn 5, Issue 1, 2011, Pages 26-32

  McKee, Jerry R ^a   Wall, Trossie ^a   Owensby, Jessica ^b  

^a Broughton Hospital   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Agranulocytosis; Clozapine; Pseudoneutropenia; Treatment Resistant schizophrenia

Indexed keywords

CLOZAPINE;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; BLOOD CELL COUNT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CAUCASIAN; CLINICAL ARTICLE; ETHNICITY; FEMALE; GRANULOCYTOPENIA; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MEDICAL RECORD REVIEW; NEUTROPENIA; NEUTROPHIL COUNT; PHYSICAL MOBILITY; SCHIZOPHRENIA; SEX; SIDE EFFECT; VALIDATION PROCESS; WAKEFULNESS;

ADULT; AGED; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; BLOOD CELL COUNT; BLOOD SPECIMEN COLLECTION; CIRCADIAN RHYTHM; CLOZAPINE; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HOSPITALIZATION; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79953826708     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.5.1.4     Document Type: Article

References (29)

1. Conley RR, Kelly DL. Management of treatment-resistant schizophrenia. Biol Psychiatry 2001;50(11):898-911.
2. Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65(4):500-508.
3. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al.; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl):1-56.
4. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al.; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-610. (Pubitemid 44464569)
5. Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 1998;59(Suppl 3):38-43. (Pubitemid 28196369)
6. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapineinduced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329(3):162-167. (Pubitemid 23195736)
7. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59(Suppl 3):3-7. (Pubitemid 28196363)
8. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006;188:255-263. (Pubitemid 43341654)
9. Novartis Pharmaceuticals. Clozapine Prescribing Information. www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf (revised March 2008) (accessed 19 February 2009).
10. Bray A. Ethnic neutropenia and clozapine. Aust N Z J Psychiatry 2008;42(4):342-345. (Pubitemid 351386495)
11. Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs 2007;21(1):25-35.
12. Esposito D, Corruble E, Hardy P, Chouinard G. Risperidone-induced morning pseudoneutropenia. Am J Psychiatry 2005;162(2):397.
13. Hummer M, Kurz M, Barnas C, Fleischhacker WW. Transient neutropenia induced by clozapine. Psychopharmacol Bull 1992;28(3):287-290.
14. Esposito D, Hardy P, Corruble E. Clozapine treatment following blood dyscrasia. Br J Psychiatry 2006:189;186. (Pubitemid 44231282)
15. Esposito D, Aouille J, Rouillon F, Limosin F. Two-year follow-up of a patient with successful continuation of clozapine treatment despite morning pseudoneutropenia. J Clin Psychiatry 2004;65(9):1281.
16. Esposito D, Rouillon F, Limosin F. Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol 2005;60(11):759-764. (Pubitemid 40394568)
17. Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull 2007;33(5):1221-1224. (Pubitemid 47347911)
18. Jilma B, Hergovich N, Stohlawetz P, Eichler HG, Bauer P, Wagner OF. Circadian variation of granulocyte colony stimulating factor levels in man. Br J Haematol 1999;106(2):368-370. (Pubitemid 29450658)
19. Ahokas A, Elonen E. Circadian rhythm of white blood cells during clozapine treatment. Psychopharmacology (Berl) 1999;144(3):301-302. (Pubitemid 29307284)
20. Esposito D, Aouille J, Rouillon F, Limosin F. Morning pseudoneutropenia during clozapine treatment. World J Biol Psychiatry 2003;4(4):192-194.
21. Hong X, Wang X. Agranulocytosis and neutropenia with typical and atypical neuroleptics. Am J Psychiatry 2001;158(10):1736-1737. (Pubitemid 32923676)
22. Esposito D, Chouinard G, Hardy P, Corruble E. Successful initiation of clozapine treatment despite morning pseudoneutropenia. Int J Neuropsychopharmacol 2006;9(4):489-491. (Pubitemid 43979710)
23. Rajagopal S. Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J 2005;81(959):545-546. (Pubitemid 41297905)
24. Mallinger JB, Lamberi JS. Clozapine--should race affect prescribing guidelines? Schizophr Res 2006;83(1):107-108.
25. Conley RR, Tamminga CA, Kelly DA, Richardson CM. Treatment-resistant schizophrenia patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999;46(1):73-77. (Pubitemid 29296819)
26. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004;30(2):193-217.
27. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 1994;55(2):44-49. (Pubitemid 24081820)
28. Jauss M, Pantel J, Werle E, Schroder J. G-CSF plasma levels in clozapine-induced neutropenia. Biol Psychiatry 2000;48(11):1113-1115.
29. Murry P, Laurent A. Is it possible to distinguish between benign and malignant neutropenia in clozapine-treated patients by means of hydrocortisone test? Psychopharmacology (Berl) 2001;158(3):329-330.